Influencing factors of PD-1/PD-L1 immune checkpoint inhibitor immunotherapy for gastric cancer

Le LIU; Wenbo QI; Yuping BAI; Qian LIU; Zhenyu YIN; Xiaomei LI; Yang YU; Le LIU; Hao CHEN

Return

Influencing factors of PD-1/PD-L1 immune checkpoint inhibitor immunotherapy for gastric cancer

Author: Le LIU ¹ ; Wenbo QI ¹ ; Yuping BAI ¹ ; Qian LIU ¹ ; Zhenyu YIN ¹ ; Xiaomei LI ¹ ; Yang YU ¹ ; Le LIU ² ; Hao CHEN ³
Author Information

1. The Second Clinical Medical College of Lanzhou University
2. The Gansu Provincial Hospital
3. The Department of Tumour Surgery, Lanzhou University Second Hospital
Publication Type:Journal Article
Keywords: Gastric cancer; Immune checkpoint; Prognosis; Tumor immune microenvironment
From: Chinese Journal of Clinical Pharmacology and Therapeutics 2022;27(1):95-101
CountryChina
Language:Chinese
Abstract: Gastric cancer has high morbidity and mortality, and limited treatment options for advanced cancer. In recent years, with the advent of targeted drugs (including VEGFR-2 antagonists, anti-HER-2 antibodies) and immunotherapeutics (such as anti-CTLA-4 antibodies, anti-PD-1/PD-L1 antibodies), the efficacy of advanced gastric cancer has been increased. Currently, the clinical data of PD-1 and its ligand PD-L1 inhibitors have achieved phased success, but which factors affect the efficacy of PD-1/PD-L1 immune checkpoint inhibitors immunotherapy, and how to select the benefited patient population and establish the prognosis evaluation system are the urgent problems to be solved. Therefore, this review elaborated the factors affecting the immunotherapy effects of PD-1/PD-L1 inhibitors from the aspects of systemic chemotherapy, intestinal microbiota, MSI, Hp infection, Epstein-Barr virus, TMB, and tumor infiltrating lymphocytes, in order to provide new ideas for clinical work.